Skip to main content
. 2022 Nov 14;13:1039157. doi: 10.3389/fimmu.2022.1039157

Figure 3.

Figure 3

Forest plots displaying the relationship between immunotherapy and overall survival (A) and cancer-specific survival (B) within different subgroups in each cohort. BOM, bone metastases only; BRM, brain metastases only; CSS, cancer-specific survival; LIM, liver metastases only; MOM, multiple organ metastases; OS, overall survival; OTM, other metastases.